Targeting FGFR3 Alterations with Adjuvant Infigratinib in Invasive Urothelial Carcinoma: the Phase III PROOF 302 Trial | Zendy

Sumanta K. Pal | Zendy; Diederik M. Somford | Zendy; Petros Grivas | Zendy; Srikala S. Sridhar | Zendy; Shilpa Gupta | Zendy; Joaquim Bellmunt | Zendy; Guru Sonpavde | Zendy; Mark T. Fleming | Zendy; Seth P. Lerner | Zendy; Yohann Loriot | Zendy; Jean H. Hoffman-Censits | Zendy; Begoña P. Valderrama | Zendy; Corina Andresen | Zendy; Marco J. Schnabel | Zendy; Suzanne Cole | Zendy; Siamak Daneshmand | Zendy

Open Access

Targeting FGFR3 Alterations with Adjuvant Infigratinib in Invasive Urothelial Carcinoma: the Phase III PROOF 302 Trial

Author(s) -

Sumanta K. Pal,

Diederik M. Somford,

Petros Grivas,

Srikala S. Sridhar,

Shilpa Gupta,

Joaquim Bellmunt,

Guru Sonpavde,

Mark T. Fleming,

Seth P. Lerner,

Yohann Loriot,

Jean H. Hoffman-Censits,

Begoña P. Valderrama,

Corina Andresen,

Marco J. Schnabel,

Suzanne Cole,

Siamak Daneshmand

Publication year - 2022

Publication title -

future oncology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.857

H-Index - 72

eISSN - 1744-8301

pISSN - 1479-6694

DOI - 10.2217/fon-2021-1629

Subject(s) - medicine , placebo , clinical endpoint , tolerability , metastatic urothelial carcinoma , oncology , adjuvant , bladder cancer , cisplatin , urothelial cancer , urology , randomized controlled trial , adverse effect , urothelial carcinoma , cancer , chemotherapy , pathology , alternative medicine

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research